[go: up one dir, main page]

IN2009CN02662A - - Google Patents

Download PDF

Info

Publication number
IN2009CN02662A
IN2009CN02662A IN2662CHN2009A IN2009CN02662A IN 2009CN02662 A IN2009CN02662 A IN 2009CN02662A IN 2662CHN2009 A IN2662CHN2009 A IN 2662CHN2009A IN 2009CN02662 A IN2009CN02662 A IN 2009CN02662A
Authority
IN
India
Prior art keywords
active substance
buprenorphine
transdermal therapeutic
therapeutic system
administering
Prior art date
Application number
Inventor
Thomas Hille
Michael Horstmann
Walter Muller
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of IN2009CN02662A publication Critical patent/IN2009CN02662A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Abstract TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING THE ACTIVE SUBSTANCE BUPRENORPHINE The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and is characterized by a considerab/y increased utilization of the active substance.
IN2662CHN2009 2006-11-21 2007-11-07 IN2009CN02662A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006054731A DE102006054731B4 (en) 2006-11-21 2006-11-21 Transdermal therapeutic system for administration of the active ingredient buprenorphine and use thereof in pain therapy
PCT/EP2007/009622 WO2008061625A2 (en) 2006-11-21 2007-11-07 Transdermal therapeutic system for administering the active substance buprenorphine

Publications (1)

Publication Number Publication Date
IN2009CN02662A true IN2009CN02662A (en) 2015-08-07

Family

ID=39326133

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2662CHN2009 IN2009CN02662A (en) 2006-11-21 2007-11-07

Country Status (25)

Country Link
US (5) US9308202B2 (en)
EP (2) EP2769714B1 (en)
JP (2) JP5763296B2 (en)
KR (1) KR101444967B1 (en)
CN (1) CN101528207B (en)
AR (1) AR064268A1 (en)
AU (1) AU2007323387B2 (en)
BR (1) BRPI0719115B8 (en)
CA (1) CA2670290C (en)
CY (2) CY1118154T1 (en)
DE (1) DE102006054731B4 (en)
DK (2) DK2094249T3 (en)
ES (2) ES2581574T3 (en)
HU (2) HUE026978T2 (en)
IL (2) IL198743A (en)
IN (1) IN2009CN02662A (en)
MX (2) MX344241B (en)
NZ (1) NZ575500A (en)
PL (2) PL2094249T3 (en)
PT (1) PT2769714E (en)
RU (1) RU2484822C2 (en)
SI (2) SI2094249T1 (en)
TW (1) TWI411452B (en)
WO (1) WO2008061625A2 (en)
ZA (1) ZA200901695B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
TWI630208B (en) 2008-12-08 2018-07-21 歐陸斯迪公司 Dihydroetorphine
RS54173B1 (en) * 2010-12-14 2015-12-31 Acino Ag TRANSDERMAL THERAPY SYSTEM FOR ACTIVE SUBSTANCE
DE102011076653A1 (en) * 2011-05-27 2012-11-29 Acino Ag Transdermal therapeutic system containing buprenorphine and an alpha hydroxy acid
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (en) 2011-11-23 2021-09-30 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
TW201338813A (en) * 2011-12-12 2013-10-01 Lohmann Therapie Syst Lts Transdermal delivery system
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN104736176B (en) * 2012-08-24 2017-10-13 英特格拉斯疗法有限公司 Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
TW201431570A (en) 2012-11-22 2014-08-16 Ucb Pharma Gmbh Multi-day patch for the transdermal administration of rotigotine
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2015008021A (en) * 2012-12-21 2016-03-04 Teikoku Pharma Usa Inc Compositions and methods for transdermal delivery of hormones and other medicinal agents.
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN103893154A (en) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 Buprenorphine-containing transdermal delivery system
US11547676B2 (en) 2012-12-28 2023-01-10 Teikoku Seiyaku Co., Ltd. Extended buprenorphine transdermal delivery compositions and methods for using the same
CN108327400B (en) * 2013-03-01 2020-02-21 松下知识产权经营株式会社 Transfer device and printing device
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
AU2014276910B2 (en) * 2013-06-04 2017-03-09 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
ES2703623T3 (en) * 2013-06-28 2019-03-11 Purdue Pharma Lp Opioid antagonists for use in the treatment of arrhythmia induced by opioid analgesics
CA2916183C (en) 2013-07-03 2022-03-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with electronic component
EP2921184A1 (en) * 2014-03-19 2015-09-23 LTS LOHMANN Therapie-Systeme AG Finishing plaster having improved tolerability and a long adhesive period and method for producing the same
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
JP6573913B2 (en) 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー Transdermal delivery system containing rotigotine
CA2948219C (en) 2014-05-20 2023-04-04 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
JP2017516768A (en) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． Natural combination hormone replacement therapy and therapy
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
CA3104099A1 (en) 2015-03-10 2016-09-15 Rhodes Technologies Acetate salt of buprenorphine and methods for preparing buprenorphine
WO2016145373A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2018526415A (en) * 2015-09-14 2018-09-13 アムニール ファーマシューティカルズ エルエルシー Transdermal delivery system
AR102214A1 (en) * 2015-10-08 2017-02-15 Amarin Tech S A A DEVICE FOR THE TRANSDERMAL ADMINISTRATION OF BUPRENORFINA
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
CA3074636C (en) * 2017-09-04 2024-04-30 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an emulsifier
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab New pharmaceutical compositions
DE102017127433A1 (en) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag TTS based on adhesive plasticizer polymer matrices
BR112020018300A2 (en) * 2018-03-13 2020-12-22 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM UNDERSTANDING A HYBRID SILICON AND ACRYLIC POLYMER
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
US11752114B2 (en) 2019-04-17 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system
FI3854388T3 (en) * 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag A transdermal treatment system with the active ingredient rotigotine and at least one non-amine-resistant silicone adhesive
JP7173415B2 (en) * 2020-08-19 2022-11-16 東洋インキＳｃホールディングス株式会社 patch

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB1136214A (en) 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
DE3939376C1 (en) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
DE4446600A1 (en) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermal absorption of active ingredients from supercooled melts
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19922662C1 (en) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermal therapeutic system (TTS) containing tolterodine
DE19958554C2 (en) * 1999-07-02 2002-06-13 Lohmann Therapie Syst Lts Microreservoir system based on polysiloxanes and ambiphilic solvents and their manufacture
PL197492B1 (en) 1999-07-02 2008-04-30 Lohmann Therapie Syst Lts Transdermal therapeutic system containing a polymer layer with microreservoirs contained therein and a method of producing membranes
SI1299104T1 (en) 2000-02-08 2009-10-31 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
WO2002083135A2 (en) 2001-02-16 2002-10-24 Grünenthal GmbH Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence
DE10141651B4 (en) 2001-08-24 2007-02-15 Lts Lohmann Therapie-Systeme Ag Transdermal Therapeutic System (TTS) with the active ingredient Fentanyl and process for its preparation
US20050118245A1 (en) 2002-03-27 2005-06-02 Wilsmann Klaus M. Assembled unit consisting of individually separable, transdermal, therapeutic systems
DE10213772A1 (en) 2002-03-27 2003-10-09 Gruenenthal Gmbh Cohesive unit of singular transdermal therapeutic systems
ES2290512T3 (en) * 2002-08-09 2008-02-16 Grunenthal Gmbh ANTIGONISTS OF THE OPIOID RECEIVER IN TRANSDERMAL SYSTEMS CONTAINING BUPRENORFINE.
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
MXPA05006334A (en) 2002-12-13 2005-08-26 Euro Celtique Sa Transdermal buprenorphine dosage regimen for analgesia.
RU2324372C2 (en) 2003-03-25 2008-05-20 Моринда, Инк. Selective inhibition of estrogen production and activity in human
DE102004045599A1 (en) 2004-09-17 2006-03-23 Grünenthal GmbH System for the sequential, transdermal administration of systemically active substances
DE102004062647A1 (en) 2004-12-21 2006-06-29 Kronotec Ag Wood fiber insulation board or mat
DE102004062614B4 (en) 2004-12-24 2011-12-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with activatable supersaturation and controlled permeation promotion and process for its preparation
TW201338813A (en) 2011-12-12 2013-10-01 Lohmann Therapie Syst Lts Transdermal delivery system
AU2013205080B2 (en) 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
AU2014276910B2 (en) 2013-06-04 2017-03-09 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system

Also Published As

Publication number Publication date
TWI411452B (en) 2013-10-11
US20160175447A1 (en) 2016-06-23
BRPI0719115A2 (en) 2013-12-10
HK1200373A1 (en) 2015-08-07
CN101528207A (en) 2009-09-09
ES2543977T3 (en) 2015-08-26
EP2094249B1 (en) 2016-04-13
HK1132921A1 (en) 2010-03-12
HUE028971T2 (en) 2017-01-30
US20170224676A1 (en) 2017-08-10
DE102006054731B4 (en) 2013-02-28
NZ575500A (en) 2011-12-22
US20100119585A1 (en) 2010-05-13
PT2769714E (en) 2015-08-05
BRPI0719115B1 (en) 2019-04-24
ES2581574T3 (en) 2016-09-06
TW200836776A (en) 2008-09-16
CA2670290C (en) 2016-05-31
DK2769714T3 (en) 2015-08-03
AR064268A1 (en) 2009-03-25
US20190192506A1 (en) 2019-06-27
US9308202B2 (en) 2016-04-12
AU2007323387B2 (en) 2014-01-09
IL245290A0 (en) 2016-06-30
PL2769714T3 (en) 2015-12-31
JP2010510259A (en) 2010-04-02
CY1118154T1 (en) 2017-06-28
DK2094249T3 (en) 2016-08-01
EP2769714A1 (en) 2014-08-27
HUE026978T2 (en) 2016-08-29
RU2484822C2 (en) 2013-06-20
AU2007323387A1 (en) 2008-05-29
SI2094249T1 (en) 2016-07-29
WO2008061625A2 (en) 2008-05-29
PL2094249T3 (en) 2017-11-30
JP2014028844A (en) 2014-02-13
KR20090082410A (en) 2009-07-30
JP5882970B2 (en) 2016-03-09
JP5763296B2 (en) 2015-08-12
US20180289698A1 (en) 2018-10-11
IL198743A (en) 2016-05-31
EP2769714B1 (en) 2015-05-06
RU2009123368A (en) 2010-12-27
BRPI0719115B8 (en) 2021-05-25
ZA200901695B (en) 2009-12-30
CY1117770T1 (en) 2017-05-17
WO2008061625A3 (en) 2008-09-18
KR101444967B1 (en) 2014-09-26
IL198743A0 (en) 2010-02-17
CN101528207B (en) 2012-12-26
DE102006054731A1 (en) 2008-05-29
MX2009005341A (en) 2009-06-01
EP2094249A2 (en) 2009-09-02
SI2769714T1 (en) 2015-09-30
MX344241B (en) 2016-12-07
CA2670290A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
IN2009CN02662A (en)
NZ720946A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
NZ628092A (en) Transdermal delivery system
NZ596879A (en) Tamper resistant dosage form comprising a matrix and melt - extruded particulates comprising a drug
IL192100A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
MX365380B (en) Hydrogel formulation comprising oxidative reductive potential water.
MX337511B (en) Medicaments and methods for treating headache.
NZ586302A (en) Pre-surgical treatment using brimonidine applied topically to reduce bleeding or bruising
WO2009026178A3 (en) High concentration local anesthetic formulations
EA200802412A1 (en) THERAPEUTIC COMBINATIONS FOR SUPPORTING MEDICAL CONDITIONS
WO2007095615A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatmentof pain
SG157402A1 (en) Use of meloxicam in veterinary medicine for the treatment of inflammatory painful diseases
MX2009014102A (en) Transdermal delivery system comprising glycopyrrolate to treat sialorrhea.
MX351514B (en) Transdermal therapeutic system for 5-aminolevulinic acid hydrochloride.
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2008063563A3 (en) Methods of treating keratin hyperproliferation disorders using mtor inhibitors
MX2010006724A (en) Therapeutic regimens for the treatment of immunoinflammatory disorders.
WO2010065069A3 (en) Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
CA2863829A1 (en) Oral unit dosage forms and uses of same for the treatment of gaucher disease
MX2008011321A (en) Pharmaceutical composition for use in treating sexually transmitted infections.
WO2011133479A3 (en) Combination therapy with a proteasome inhibitor and a gallium complex
WO2008060381A3 (en) Method for treating pain or opioid dependence using a specific type of non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator
MD3284G2 (en) Method of treatment of allergic rhinitis, atopic dermatitis and chronic recurrent urticaria
UA94079C2 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
JO2586B1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain